Wikipedia - Benutzerbeiträge [de]

Rednaxela Terrace

2018-09-05T01:47:57Z

DividedFrame: /* History */ Style

[[File:Rednaxelaterrace.jpg|thumb|A road Sign of Rednaxela Terrace]]
[[File:Ophthalmologist Business Card of Doctor Jose Rizal from Hong Kong End of 19 Century.jpg|thumb|Dr. José Rizal's Business Card, showing his residence at No.2 Rednaxela Terrace]]
'''Rednaxela Terrace''' ({{zh|t=列拿士地臺}}) is a pedestrian-only street in [[Mid-levels]], [[Hong Kong]].

It is {{convert|63|m}} long and junctions [[Shelley Street]] to the west and [[Peel Street, Hong Kong|Peel Street]] to the east.<ref name=stheadline181874/>

==Name==
Although there aren't any official conclusions to the origin of the name, it is believed that the road was part of the property owned by a Mr. Alexander, and 'Rednaxela' is an understandable transposition of the English name '[[Alexander]]', since the Chinese language is written right to left.<ref>{{cite book |title= Signs of a Colonial Era|last1= Yanne|first1=Andrew|last2= Heller|first2= Gillis|year= 2009|publisher=[[Hong Kong University Press]]|page= 143|location= |isbn= 9789622099449}}</ref><ref name=scmp1987092>{{cite web|url=http://www.scmp.com/lifestyle/travel-leisure/article/1987092/stories-behind-hong-kong-street-names-rednaxela-terrace-and|title=Stories behind Hong Kong street names: Rednaxela Terrace and its famous resident|work=South China Morning Post}}</ref> Most of the naming errors in Hong Kong are a result of incorrect or inaccurate translations or transliterations, so some believe the explanation of this unique example of right-to-left transposition error in Hong Kong under colonial bureaucrats inconceivable. Another explanation is that the name is linked to abolitionist [[Robert Alexander Young]], who was known to have used the name "Rednaxela" in his 1829 work ''Ethiopian Manifesto''.<ref name=stheadline181874>{{cite web|url=http://hd.stheadline.com/culture/culture_content.asp?contid=181874&srctype=g|title= 列拿士地臺的故事|work=Headline Daily|language=zh}}</ref> Whatever the source of the name, Chinese transliteration followed suit and was adopted by the neighbourhood, and the government never made any further alterations.<ref name=stheadline181874/>

==History==
From December 1891 to June 1892, the Filipino revolutionary and national hero [[José Rizal]] lived with his family at Number 2, Rednaxela Terrace, then working as an eye clinician in Hong Kong. The Hong Kong government erected a commemorative plaque in 2004 on the intersection of Rednaxela Terrace and Shelley Street to honour Rizal.<ref name=stheadline181874/><ref name=scmp1987092/>

==References==
{{reflist|colwidth=30em}}

{{commons category|Rednaxela Terrace}}
[[Category:Roads in Hong Kong]]
[[Category:Mid-Levels]]

{{HongKong-road-stub}}

Brand im brasilianischen Nationalmuseum

2018-09-03T05:06:52Z

DividedFrame: /* top */ Style

{{Current||current disaster|date=September 2018}}
{{Infobox event
| title = National Museum of Brazil Fire
| image = Fire at Museu Nacional 05.jpg
| image_size = 300px
| image_alt = The National Museum of Brazil burning behind the statue of [[Dom Pedro II]]
| caption = The National Museum of Brazil burning behind the statue of [[Dom Pedro II]]
| time =
| duration =
| date = {{start date|2018|9|2}}
| venue = [[National Museum of Brazil]]
| location =
| coordinates = 
| also_known_as =
| type = Fire incident
| cause = Unknown
| motive =
| target =
| notes =
| reported deaths = 0
| reported injuries = 0
}}

On September 2, 2018, at around 19:30 local time, a large fire broke out at the [[Paço de São Cristóvão]], which houses the [[National Museum of Brazil]], in [[Rio de Janeiro]]. Reaction to the cultural loss was quick, as the museum's holdings include over 20 million items, with Brazil's president [[Michel Temer]] calling the loss of the historical and cultural heritage "incalculable". The cause of the fire could not be determined so far, but many connected it to the museum's lack of funding. Although the building had been heavily damaged, no injuries were reported.

== Background ==
With continued budget cuts, the museum did not receive its sum of R$520,000 per year, necessary for its maintenance, since 2014, even with visible signs of poor conservation, such as peeled walls and exposed wires.<ref name="Incêndio - Folha">{{Cite news|url=https://www1.folha.uol.com.br/cotidiano/2018/09/incendio-atinge-o-museu-nacional-na-quinta-da-boa-vista-no-rio.shtml|title=Incêndio atinge o Museu Nacional na Quinta da Boa Vista, no Rio. Mais antigo do país, museu tem 20 milhões de itens e apresentava problemas de manutenção|date=2018-09-02|work=Folha de São Paulo|access-date=2018-09-02|language=pt|trans-title=Fire hit the National Museum, at the Quinta da Boa Vista, in Rio. Most ancient of the country, the museum has 20 million items and presented maintenance issues}}</ref> The museum had celebrated 200 years in June 2018, amidst a situation of abandonment.<ref name=":2">{{Cite news|url=https://brasil.estadao.com.br/noticias/geral,incendio-atinge-museu-nacional-no-rio,70002484984|title=Incêndio atinge Museu Nacional, no Rio - Brasil|date=2018-09-02|work=Estado de S.Paulo|access-date=2018-09-02|language=pt|trans-title=Fire hit the National Museum, in Rio - Brazil}}</ref>

The museum vice-director, Luiz Fernando Dias Duarte, referred to the neglect suffered by the museum during successive governments.<ref name=":4">{{Cite news|url=https://g1.globo.com/rj/rio-de-janeiro/noticia/2018/09/02/vice-diretor-do-museu-nacional-cita-descaso-de-varios-governos.ghtml|title=Vice-diretor do Museu Nacional cita 'descaso' de vários governos e que incêndio destruiu tudo|date=2018-09-02|work=G1|access-date=2018-09-02|language=pt|trans-title=Vice-director of the National Museum cites 'neglect' of multiple governments and that the fire destroyed everything}}</ref>

== Fire ==
On September 2, 2018, shortly after the closing of access by the public, a fire of great proportions hit all three floors of the National Museum building, at the [[Quinta da Boa Vista]] park.<ref name="bbc_first">{{Cite web|url=https://www.bbc.co.uk/news/world-latin-america-45392668|title=Fire engulfs 200-year-old Brazil museum|last=|first=|date=2 September 2018|website=BBC|archive-url=https://web.archive.org/web/20180903005443/https://www.bbc.co.uk/news/world-latin-america-45392668|archive-date=2 September 2018|dead-url=no|access-date=2 September 2018}}</ref><ref name="reuters_first">{{Cite web|url=https://www.reuters.com/article/us-brazil-fire-museum/rios-200-year-old-national-museum-hit-by-massive-fire-idUSKCN1LJ00L|title=Rio's 200-year old National Museum hit by massive fire|last=|first=|date=2 September 2018|website=[[Reuters]]|archive-url=https://web.archive.org/web/20180903003435/https://www.reuters.com/article/us-brazil-fire-museum/rios-200-year-old-national-museum-hit-by-massive-fire-idUSKCN1LJ00L|archive-date=2 September 2018|dead-url=no|access-date=2 September 2018}}</ref><ref name="Incêndio - G1">{{Cite news|url=https://g1.globo.com/rj/rio-de-janeiro/noticia/2018/09/02/incendio-atinge-a-quinta-da-boa-vista-rio.ghtml|title=Incêndio de grandes proporções atinge o Museu Nacional, na Quinta da Boa Vista. Ainda não há informações sobre feridos ou sobre as causas do fogo, que começou após o fechamento do museu a visitantes. Instituição criada por Dom João VI tem 200 anos de história.|date=2018-09-02|work=G1|access-date=2018-09-02|language=pt|trans-title=Fire of great proportions hit the National Museum, at Quinta da Boa Vista. There are still no information on injured or the causes of the fire, that began soon after the closing of the museum to visitors. Institution created by Dom João VI has 200 years of history.}}</ref> The firefighters were called at 19:30 (local time),<ref>{{Cite news|url=https://veja.abril.com.br/brasil/incendio-destroi-predio-do-museu-nacional-no-rio-de-janeiro/|title=Incêndio destrói prédio do Museu Nacional no Rio de Janeiro|date=2018-09-02|work=VEJA.com|access-date=2018-09-02|language=pt|trans-title=Fire destroys building of the National Museum in Rio de Janeiro}}</ref> arriving quickly to the scene.<ref name=":2" />

By 21:00, the fire was out of control, with great flames and occasional crashes,<ref name=":0">{{Cite news|url=https://www.terra.com.br/noticias/brasil/cidades/incendio-atinge-museu-nacional-no-rio,67b952818be2a47677b2bb6dab5559bfa63ih1tb.html|title=Incêndio atinge Museu Nacional, no Rio|date=2018-09-02|work=Terra Online|access-date=2018-09-02|language=pt|trans-title=Fire hit the National Museum, in Rio}}</ref> being fought by firefighters of four quarters.<ref name=":3">{{Cite news|url=http://agenciabrasil.ebc.com.br/geral/noticia/2018-09/incendio-no-museu-nacional-destroi-colecoes-e-exposicoes|title=Incêndio no Museu Nacional destrói coleções e exposições|date=2018-09-02|work=Agência Brasil|access-date=2018-09-02|language=pt|trans-title=Fire in the National Museum destroys collections and expositions}}</ref> Dozens of people went to Quinta da Boa Vista to see the fire.<ref name=":2" />

At 21:15, a specialized team of firefighters entered the building to try to block areas still not hit by the flames, and to evaluate the extension of the damage.<ref name=":1">{{Cite news|url=https://istoe.com.br/parte-do-teto-do-museu-nacional-ja-desabou-com-incendio/|title=Parte do teto do Museu Nacional já desabou com incêndio|date=2018-09-02|work=ISTOÉ Independente|access-date=2018-09-02|language=pt|trans-title=Part of the ceiling of the National Museum has already fallen due to the fire}}</ref>

By 21:30, the whole building had been engulfed by the fire, as well as two exhibitions that were in two areas at the front of the main building. The four security guards who were working at the museum managed to escape, there have been no reports of casualties.<ref name=":3" />

At 21:45, firefighters of three corporations were fighting the fire. Two [[fire engine]]s with [[Turntable ladder|turntable ladders]] were being used, with two water trucks taking turns in the supply of water for the firemen.<ref name=":1" />

At 22:00, dozens of employees of the museum were following the fight against the flames. Two floors of the building were already destroyed, and the ceiling had fallen. According to Edson Vargas da Silva, librarian and an employee for 43 years at the museum, who was witnessing the destruction, "There is too much paper, the wood floor, too many things that burn quickly."<ref name=":1" />

== Aftermath ==
An assessment of what has been destroyed is yet to be completed, as the fire was too intense, and there was the risk of explosions.<ref name=":3" />

A portion of the museum's collection is housed elsewhere and has not been affected. The fire has consumed all that was being exhibited. The [[Rio de Janeiro Zoological Garden]], located very close to the National Museum, was not damaged.<ref name=":1" />

== Reactions ==
The president of the [[National Institute of Historic and Artistic Heritage]], Kátia Bogéa, commented, "It's a national and worldwide tragedy. Everybody can see that this is not a loss for the Brazilian people, but for the whole humanity... It is an announced tragedy, as for a long time we knew that the Brazilian cultural heritage does not have a budget".<ref name="reperc_g1">{{Cite news|url=https://g1.globo.com/rj/rio-de-janeiro/noticia/2018/09/02/incendio-no-museu-nacional-veja-a-repercussao.ghtml|title=Incêndio no Museu Nacional: veja a repercussão|date=2018-09-02|work=G1|access-date=2018-09-02|language=pt|trans-title=Fire in the National Museum: see the repercussion}}</ref>

Brazil's president, [[Michel Temer]], said, "The loss of the National Museum is incalculable for Brazil. Today is a tragic day for our country's museology. Two hundred years of work, research and knowledge were lost. The value for our history can not measured, due to the damage to the building that housed the royal family during the Empire. It is a sad day for all Brazilians."<ref name="reperc_g1"/><ref>{{Cite web|url=https://www.theguardian.com/world/2018/sep/03/fire-engulfs-brazil-national-museum-rio|title='200 years of knowledge lost': fire engulfs Brazil's national museum|last=Phillips|first=Dom|date=3 September 2018|website=The Guardian|dead-url=no|access-date=3 September 2018}}</ref>

== References ==
{{commonscat|2018 fire at the Museu Nacional, Rio de Janeiro|National Museum of Brazil fire}}
{{reflist}}

[[Category:2018 disasters in Brazil]]
[[Category:2018 fires]]
[[Category:Fires in Brazil]]
[[Category:Museums in Rio de Janeiro (city)]]
[[Category:September 2018 events in South America]]

Brand im brasilianischen Nationalmuseum

2018-09-03T05:01:12Z

DividedFrame: /* Reactions */ Style

{{Current||current disaster|date=September 2018}}
{{Infobox event
| title = National Museum of Brazil Fire
| image = Fire at Museu Nacional 05.jpg
| image_size = 300px
| image_alt = The National Museum of Brazil burning behind the statue of [[Dom Pedro II]]
| caption = The National Museum of Brazil burning behind the statue of [[Dom Pedro II]]
| time =
| duration =
| date = {{start date|2018|9|2}}
| venue = [[National Museum of Brazil]]
| location =
| coordinates = 
| also_known_as =
| type = Fire incident
| cause = Unknown
| motive =
| target =
| notes =
| reported deaths = 0
| reported injuries = 0
}}

On September 2, 2018, a large fire broke out at the [[Paço de São Cristóvão]], which houses the [[National Museum of Brazil]], in [[Rio de Janeiro]]. The fire began at around 19:30 local time. Brazil's president [[Michel Temer]] said that the loss of the historical and cultural heritage was "incalculable". The cause of the fire could not be determined so far, but many connected it to the museum's lack of funding. Although the building had been heavily damaged, no injuries were reported.

== Background ==
With continued budget cuts, the museum did not receive its sum of R$520,000 per year, necessary for its maintenance, since 2014, even with visible signs of poor conservation, such as peeled walls and exposed wires.<ref name="Incêndio - Folha">{{Cite news|url=https://www1.folha.uol.com.br/cotidiano/2018/09/incendio-atinge-o-museu-nacional-na-quinta-da-boa-vista-no-rio.shtml|title=Incêndio atinge o Museu Nacional na Quinta da Boa Vista, no Rio. Mais antigo do país, museu tem 20 milhões de itens e apresentava problemas de manutenção|date=2018-09-02|work=Folha de São Paulo|access-date=2018-09-02|language=pt|trans-title=Fire hit the National Museum, at the Quinta da Boa Vista, in Rio. Most ancient of the country, the museum has 20 million items and presented maintenance issues}}</ref> The museum had celebrated 200 years in June 2018, amidst a situation of abandonment.<ref name=":2">{{Cite news|url=https://brasil.estadao.com.br/noticias/geral,incendio-atinge-museu-nacional-no-rio,70002484984|title=Incêndio atinge Museu Nacional, no Rio - Brasil|date=2018-09-02|work=Estado de S.Paulo|access-date=2018-09-02|language=pt|trans-title=Fire hit the National Museum, in Rio - Brazil}}</ref>

The museum vice-director, Luiz Fernando Dias Duarte, referred to the neglect suffered by the museum during successive governments.<ref name=":4">{{Cite news|url=https://g1.globo.com/rj/rio-de-janeiro/noticia/2018/09/02/vice-diretor-do-museu-nacional-cita-descaso-de-varios-governos.ghtml|title=Vice-diretor do Museu Nacional cita 'descaso' de vários governos e que incêndio destruiu tudo|date=2018-09-02|work=G1|access-date=2018-09-02|language=pt|trans-title=Vice-director of the National Museum cites 'neglect' of multiple governments and that the fire destroyed everything}}</ref>

== Fire ==
On September 2, 2018, shortly after the closing of access by the public, a fire of great proportions hit all three floors of the National Museum building, at the [[Quinta da Boa Vista]] park.<ref name="bbc_first">{{Cite web|url=https://www.bbc.co.uk/news/world-latin-america-45392668|title=Fire engulfs 200-year-old Brazil museum|last=|first=|date=2 September 2018|website=BBC|archive-url=https://web.archive.org/web/20180903005443/https://www.bbc.co.uk/news/world-latin-america-45392668|archive-date=2 September 2018|dead-url=no|access-date=2 September 2018}}</ref><ref name="reuters_first">{{Cite web|url=https://www.reuters.com/article/us-brazil-fire-museum/rios-200-year-old-national-museum-hit-by-massive-fire-idUSKCN1LJ00L|title=Rio's 200-year old National Museum hit by massive fire|last=|first=|date=2 September 2018|website=[[Reuters]]|archive-url=https://web.archive.org/web/20180903003435/https://www.reuters.com/article/us-brazil-fire-museum/rios-200-year-old-national-museum-hit-by-massive-fire-idUSKCN1LJ00L|archive-date=2 September 2018|dead-url=no|access-date=2 September 2018}}</ref><ref name="Incêndio - G1">{{Cite news|url=https://g1.globo.com/rj/rio-de-janeiro/noticia/2018/09/02/incendio-atinge-a-quinta-da-boa-vista-rio.ghtml|title=Incêndio de grandes proporções atinge o Museu Nacional, na Quinta da Boa Vista. Ainda não há informações sobre feridos ou sobre as causas do fogo, que começou após o fechamento do museu a visitantes. Instituição criada por Dom João VI tem 200 anos de história.|date=2018-09-02|work=G1|access-date=2018-09-02|language=pt|trans-title=Fire of great proportions hit the National Museum, at Quinta da Boa Vista. There are still no information on injured or the causes of the fire, that began soon after the closing of the museum to visitors. Institution created by Dom João VI has 200 years of history.}}</ref> The firefighters were called at 19:30 (local time),<ref>{{Cite news|url=https://veja.abril.com.br/brasil/incendio-destroi-predio-do-museu-nacional-no-rio-de-janeiro/|title=Incêndio destrói prédio do Museu Nacional no Rio de Janeiro|date=2018-09-02|work=VEJA.com|access-date=2018-09-02|language=pt|trans-title=Fire destroys building of the National Museum in Rio de Janeiro}}</ref> arriving quickly to the scene.<ref name=":2" />

By 21:00, the fire was out of control, with great flames and occasional crashes,<ref name=":0">{{Cite news|url=https://www.terra.com.br/noticias/brasil/cidades/incendio-atinge-museu-nacional-no-rio,67b952818be2a47677b2bb6dab5559bfa63ih1tb.html|title=Incêndio atinge Museu Nacional, no Rio|date=2018-09-02|work=Terra Online|access-date=2018-09-02|language=pt|trans-title=Fire hit the National Museum, in Rio}}</ref> being fought by firefighters of four quarters.<ref name=":3">{{Cite news|url=http://agenciabrasil.ebc.com.br/geral/noticia/2018-09/incendio-no-museu-nacional-destroi-colecoes-e-exposicoes|title=Incêndio no Museu Nacional destrói coleções e exposições|date=2018-09-02|work=Agência Brasil|access-date=2018-09-02|language=pt|trans-title=Fire in the National Museum destroys collections and expositions}}</ref> Dozens of people went to Quinta da Boa Vista to see the fire.<ref name=":2" />

At 21:15, a specialized team of firefighters entered the building to try to block areas still not hit by the flames, and to evaluate the extension of the damage.<ref name=":1">{{Cite news|url=https://istoe.com.br/parte-do-teto-do-museu-nacional-ja-desabou-com-incendio/|title=Parte do teto do Museu Nacional já desabou com incêndio|date=2018-09-02|work=ISTOÉ Independente|access-date=2018-09-02|language=pt|trans-title=Part of the ceiling of the National Museum has already fallen due to the fire}}</ref>

By 21:30, the whole building had been engulfed by the fire, as well as two exhibitions that were in two areas at the front of the main building. The four security guards who were working at the museum managed to escape, there have been no reports of casualties.<ref name=":3" />

At 21:45, firefighters of three corporations were fighting the fire. Two [[fire engine]]s with [[Turntable ladder|turntable ladders]] were being used, with two water trucks taking turns in the supply of water for the firemen.<ref name=":1" />

At 22:00, dozens of employees of the museum were following the fight against the flames. Two floors of the building were already destroyed, and the ceiling had fallen. According to Edson Vargas da Silva, librarian and an employee for 43 years at the museum, who was witnessing the destruction, "There is too much paper, the wood floor, too many things that burn quickly."<ref name=":1" />

== Aftermath ==
An assessment of what has been destroyed is yet to be completed, as the fire was too intense, and there was the risk of explosions.<ref name=":3" />

A portion of the museum's collection is housed elsewhere and has not been affected. The fire has consumed all that was being exhibited. The [[Rio de Janeiro Zoological Garden]], located very close to the National Museum, was not damaged.<ref name=":1" />

== Reactions ==
The president of the [[National Institute of Historic and Artistic Heritage]], Kátia Bogéa, commented, "It's a national and worldwide tragedy. Everybody can see that this is not a loss for the Brazilian people, but for the whole humanity... It is an announced tragedy, as for a long time we knew that the Brazilian cultural heritage does not have a budget".<ref name="reperc_g1">{{Cite news|url=https://g1.globo.com/rj/rio-de-janeiro/noticia/2018/09/02/incendio-no-museu-nacional-veja-a-repercussao.ghtml|title=Incêndio no Museu Nacional: veja a repercussão|date=2018-09-02|work=G1|access-date=2018-09-02|language=pt|trans-title=Fire in the National Museum: see the repercussion}}</ref>

Brazil's president, [[Michel Temer]], said, "The loss of the National Museum is incalculable for Brazil. Today is a tragic day for our country's museology. Two hundred years of work, research and knowledge were lost. The value for our history can not measured, due to the damage to the building that housed the royal family during the Empire. It is a sad day for all Brazilians."<ref name="reperc_g1"/><ref>{{Cite web|url=https://www.theguardian.com/world/2018/sep/03/fire-engulfs-brazil-national-museum-rio|title='200 years of knowledge lost': fire engulfs Brazil's national museum|last=Phillips|first=Dom|date=3 September 2018|website=The Guardian|dead-url=no|access-date=3 September 2018}}</ref>

== References ==
{{commonscat|2018 fire at the Museu Nacional, Rio de Janeiro|National Museum of Brazil fire}}
{{reflist}}

[[Category:2018 disasters in Brazil]]
[[Category:2018 fires]]
[[Category:Fires in Brazil]]
[[Category:Museums in Rio de Janeiro (city)]]
[[Category:September 2018 events in South America]]

Tecovirimat

2018-07-16T03:23:34Z

DividedFrame: /* top */ Reference: NEJM "Oral Tecovirimat for the Treatment of Smallpox"

{{Drugbox
| verifiedrevid =
| IUPAC_name = ''N''-<nowiki/>{3,5-Dioxo-4- azatetracyclo[5.3.2.0{2,6}.0{8,10}]dodec-11-en-4- yl}-4-(trifluoromethyl)benzamide
| image = Tecovirimat.svg
| width = 200

| tradename =
| licence_EU =
| licence_US =
| pregnancy_US =
| legal_status = Prescription only (US)<ref>https://investor.siga.com/news-releases/news-release-details/us-food-and-drug-administration-approves-siga-technologies</ref>

| bioavailability =
| metabolism =
| excretion =

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID =
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = F925RR824R
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG =
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1242629
| synonyms = ST-246

| C=19 | H=15 | F=3 | N=2 | O=3
| molecular_weight = base: 376.3 g/mol
| smiles = FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)C2C(C3C=CC2C2CC32)C1=O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H15F3N2O3/c20-19(21,22)9-3-1-8(2-4-9)16(25)23-24-17(26)14-10-5-6-11(13-7-12(10)13)15(14)18(24)27/h1-6,10-15H,7H2,(H,23,25)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = CSKDFZIMJXRJGH-UHFFFAOYSA-N
}}

'''Tecovirimat''' ('''ST-246''' or '''Tpoxx''')<ref name="nyt-2018-07">{{cite web |last1=McNeil Jr. |first1=Donald G. |title=Drug to Treat Smallpox Approved by F.D.A., a Move Against Bioterrorism |url=https://www.nytimes.com/2018/07/13/health/smallpox-drug-fda-bioterrorism.html |website=The New York Times |publisher=The New York Times |accessdate=16 July 2018}}</ref> is an [[Antiviral drug|antiviral]] with activity against [[orthopoxviruses]] (such as [[smallpox]]) which is currently undergoing clinical trials. Originally researched by the [[National Institute of Allergy and Infectious Diseases]], the drug was previously owned by [[Viropharma]] and discovered in collaboration with scientists at [[USAMRIID]]. It is currently owned and manufactured by [[Siga Technologies]], a pharmaceutical company in the [[biodefense]] arena that won a government contract to develop the drug.

The drug works by blocking cellular transmission of the virus, thus preventing the disease.<ref name="NEJMoa1705688">{{cite journal |last1=Grosenbach |first1=Douglas W. |last2=Honeychurch |first2=Kady |last3=Rose |first3=Eric A. |last4=Chinsangaram |first4=Jarasvech |last5=Frimm |first5=Annie |last6=Maiti |first6=Biswajit |last7=Lovejoy |first7=Candace |last8=Meara |first8=Ingrid |last9=Long |first9=Paul |last10=Hruby |first10=Dennis E. |title=Oral Tecovirimat for the Treatment of Smallpox |journal=N Engl J Med |date=5 July 2018 |volume=379 |pages=44-53 |doi=10.1056/NEJMoa1705688 |url=https://www.nejm.org/doi/full/10.1056/NEJMoa1705688 |accessdate=16 July 2018}}</ref> Tecovirimat has been effective in laboratory testing; it has been shown to protect animals from [[monkeypox]] and [[rabbitpox]] and causes no serious side effects in humans.<ref name="nyt-2018-07" /> However, tecovirimat has never been used to treat a human with smallpox due to the disease's successful eradication.

Two million doses of tecovirimat are stockpiled in the US [[Strategic National Stockpile]] as a defense against a smallpox outbreak.<ref>{{cite journal | doi = 10.1371/journal.ppat.1004108| pmid = 24789223| title = Are We There Yet? The Smallpox Research Agenda Using Variola Virus| journal = PLoS Pathogens| volume = 10| issue = 5| pages = e1004108| year = 2014| last1 = Damon| first1 = Inger K.| last2 = Damaso| first2 = Clarissa R.| last3 = McFadden| first3 = Grant| pmc=4006926}}</ref><ref>https://www.sciencenews.org/article/first-smallpox-treatment-one-step-closer-fda-approval</ref>

==Clinical study==
The results of clinical trials involving tecovirimat supports its use against smallpox and other related orthopoxviruses. It has shown potential for a variety of uses including [[prophylaxis]], as a post-exposure therapeutic, as a therapeutic and an adjunct to vaccination.<ref>[http://www.siga.com/index.php?ID=9 Siga Technologies]</ref>

Tecovirimat can be taken orally and has recently been granted permission to conduct Phase II trials by the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA). In Phase I trials tecovirimat was generally well tolerated with no serious adverse events.<ref>{{cite journal | pmc = 2346641| year = 2008| author1 = Jordan| first1 = R| title = Single-Dose Safety and Pharmacokinetics of ST-246, a Novel Orthopoxvirus Egress Inhibitor| journal = Antimicrobial Agents and Chemotherapy| volume = 52| issue = 5| pages = 1721–1727| last2 = Tien| first2 = D| last3 = Bolken| first3 = T. C.| last4 = Jones| first4 = K. F.| last5 = Tyavanagimatt| first5 = S. R.| last6 = Strasser| first6 = J| last7 = Frimm| first7 = A| last8 = Corrado| first8 = M. L.| last9 = Strome| first9 = P. G.| last10 = Hruby| first10 = D. E.| doi = 10.1128/AAC.01303-07| pmid = 18316519}}</ref> Due to its importance for biodefense, the FDA has designated tecovirimat for 'fast-track' status, creating a path for expedited FDA review and eventual regulatory approval. On July 13, 2018, FDA announced approval of Tecovirimat.<ref>[https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm613496.htm U.S. Food and Drug Administration]</ref>

==Operating mechanism==
Tecovirimat inhibits the function of a major [[Viral envelope|envelope protein]] required for the production of extracellar virus. Thus the virus is prevented from leaving an infected cell and the spread of the virus within the body is prevented.<ref>{{cite journal | pmc = 1235851| year = 2005| author1 = Yang| first1 = G| title = An Orally Bioavailable Antipoxvirus Compound (ST-246) Inhibits Extracellular Virus Formation and Protects Mice from Lethal Orthopoxvirus Challenge| journal = Journal of Virology| volume = 79| issue = 20| pages = 13139–13149| last2 = Pevear| first2 = D. C.| last3 = Davies| first3 = M. H.| last4 = Collett| first4 = M. S.| last5 = Bailey| first5 = T| last6 = Rippen| first6 = S| last7 = Barone| first7 = L| last8 = Burns| first8 = C| last9 = Rhodes| first9 = G| last10 = Tohan| first10 = S| last11 = Huggins| first11 = J. W.| last12 = Baker| first12 = R. O.| last13 = Buller| first13 = R. L.| last14 = Touchette| first14 = E| last15 = Waller| first15 = K| last16 = Schriewer| first16 = J| last17 = Neyts| first17 = J| last18 = Declercq| first18 = E| last19 = Jones| first19 = K| last20 = Hruby| first20 = D| last21 = Jordan| first21 = R| doi = 10.1128/JVI.79.20.13139-13149.2005| pmid = 16189015}}</ref>

==References==
<references/>

[[Category:Antivirals]]
[[Category:Poxviruses]]
[[Category:Imides]]
[[Category:Hydrazides]]
[[Category:Experimental drugs]]
[[Category:Trifluoromethyl compounds]]
[[Category:Benzamides]]
[[Category:Nitrogen heterocycles]]
[[Category:Cyclopropanes]]

Tecovirimat

2018-07-16T03:16:16Z

DividedFrame: /* Clinical study */ Capitalization

{{Drugbox
| verifiedrevid =
| IUPAC_name = ''N''-<nowiki/>{3,5-Dioxo-4- azatetracyclo[5.3.2.0{2,6}.0{8,10}]dodec-11-en-4- yl}-4-(trifluoromethyl)benzamide
| image = Tecovirimat.svg
| width = 200

| tradename =
| licence_EU =
| licence_US =
| pregnancy_US =
| legal_status = Prescription only (US)<ref>https://investor.siga.com/news-releases/news-release-details/us-food-and-drug-administration-approves-siga-technologies</ref>

| bioavailability =
| metabolism =
| excretion =

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID =
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = F925RR824R
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG =
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1242629
| synonyms = ST-246

| C=19 | H=15 | F=3 | N=2 | O=3
| molecular_weight = base: 376.3 g/mol
| smiles = FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)C2C(C3C=CC2C2CC32)C1=O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H15F3N2O3/c20-19(21,22)9-3-1-8(2-4-9)16(25)23-24-17(26)14-10-5-6-11(13-7-12(10)13)15(14)18(24)27/h1-6,10-15H,7H2,(H,23,25)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = CSKDFZIMJXRJGH-UHFFFAOYSA-N
}}

'''Tecovirimat''' ('''ST-246''' or '''Tpoxx''')<ref name="nyt-2018-07">{{cite web |last1=McNeil Jr. |first1=Donald G. |title=Drug to Treat Smallpox Approved by F.D.A., a Move Against Bioterrorism |url=https://www.nytimes.com/2018/07/13/health/smallpox-drug-fda-bioterrorism.html |website=The New York Times |publisher=The New York Times |accessdate=16 July 2018}}</ref> is an [[Antiviral drug|antiviral]] with activity against [[orthopoxviruses]] (such as [[smallpox]]) which is currently undergoing clinical trials. Originally researched by the [[National Institute of Allergy and Infectious Diseases]], the drug was previously owned by [[Viropharma]] and discovered in collaboration with scientists at [[USAMRIID]]. It is currently owned and manufactured by [[Siga Technologies]], a pharmaceutical company in the [[biodefense]] arena that won a government contract to develop the drug.

The drug works by blocking cellular transmission of the virus, thus preventing the disease. Tecovirimat has been effective in laboratory testing; it has been shown to protect animals from [[monkeypox]] and [[rabbitpox]] and causes no serious side effects in humans.<ref name="nyt-2018-07" /> However, tecovirimat has never been used to treat a human with smallpox due to the disease's successful eradication.

Two million doses of tecovirimat are stockpiled in the US [[Strategic National Stockpile]] as a defense against a smallpox outbreak.<ref>{{cite journal | doi = 10.1371/journal.ppat.1004108| pmid = 24789223| title = Are We There Yet? The Smallpox Research Agenda Using Variola Virus| journal = PLoS Pathogens| volume = 10| issue = 5| pages = e1004108| year = 2014| last1 = Damon| first1 = Inger K.| last2 = Damaso| first2 = Clarissa R.| last3 = McFadden| first3 = Grant| pmc=4006926}}</ref><ref>https://www.sciencenews.org/article/first-smallpox-treatment-one-step-closer-fda-approval</ref>

==Clinical study==
The results of clinical trials involving tecovirimat supports its use against smallpox and other related orthopoxviruses. It has shown potential for a variety of uses including [[prophylaxis]], as a post-exposure therapeutic, as a therapeutic and an adjunct to vaccination.<ref>[http://www.siga.com/index.php?ID=9 Siga Technologies]</ref>

Tecovirimat can be taken orally and has recently been granted permission to conduct Phase II trials by the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA). In Phase I trials tecovirimat was generally well tolerated with no serious adverse events.<ref>{{cite journal | pmc = 2346641| year = 2008| author1 = Jordan| first1 = R| title = Single-Dose Safety and Pharmacokinetics of ST-246, a Novel Orthopoxvirus Egress Inhibitor| journal = Antimicrobial Agents and Chemotherapy| volume = 52| issue = 5| pages = 1721–1727| last2 = Tien| first2 = D| last3 = Bolken| first3 = T. C.| last4 = Jones| first4 = K. F.| last5 = Tyavanagimatt| first5 = S. R.| last6 = Strasser| first6 = J| last7 = Frimm| first7 = A| last8 = Corrado| first8 = M. L.| last9 = Strome| first9 = P. G.| last10 = Hruby| first10 = D. E.| doi = 10.1128/AAC.01303-07| pmid = 18316519}}</ref> Due to its importance for biodefense, the FDA has designated tecovirimat for 'fast-track' status, creating a path for expedited FDA review and eventual regulatory approval. On July 13, 2018, FDA announced approval of Tecovirimat.<ref>[https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm613496.htm U.S. Food and Drug Administration]</ref>

==Operating mechanism==
Tecovirimat inhibits the function of a major [[Viral envelope|envelope protein]] required for the production of extracellar virus. Thus the virus is prevented from leaving an infected cell and the spread of the virus within the body is prevented.<ref>{{cite journal | pmc = 1235851| year = 2005| author1 = Yang| first1 = G| title = An Orally Bioavailable Antipoxvirus Compound (ST-246) Inhibits Extracellular Virus Formation and Protects Mice from Lethal Orthopoxvirus Challenge| journal = Journal of Virology| volume = 79| issue = 20| pages = 13139–13149| last2 = Pevear| first2 = D. C.| last3 = Davies| first3 = M. H.| last4 = Collett| first4 = M. S.| last5 = Bailey| first5 = T| last6 = Rippen| first6 = S| last7 = Barone| first7 = L| last8 = Burns| first8 = C| last9 = Rhodes| first9 = G| last10 = Tohan| first10 = S| last11 = Huggins| first11 = J. W.| last12 = Baker| first12 = R. O.| last13 = Buller| first13 = R. L.| last14 = Touchette| first14 = E| last15 = Waller| first15 = K| last16 = Schriewer| first16 = J| last17 = Neyts| first17 = J| last18 = Declercq| first18 = E| last19 = Jones| first19 = K| last20 = Hruby| first20 = D| last21 = Jordan| first21 = R| doi = 10.1128/JVI.79.20.13139-13149.2005| pmid = 16189015}}</ref>

==References==
<references/>

[[Category:Antivirals]]
[[Category:Poxviruses]]
[[Category:Imides]]
[[Category:Hydrazides]]
[[Category:Experimental drugs]]
[[Category:Trifluoromethyl compounds]]
[[Category:Benzamides]]
[[Category:Nitrogen heterocycles]]
[[Category:Cyclopropanes]]

Tecovirimat

2018-07-16T03:10:17Z

DividedFrame: /* top */ Added information from NYT article

{{Drugbox
| verifiedrevid =
| IUPAC_name = ''N''-<nowiki/>{3,5-Dioxo-4- azatetracyclo[5.3.2.0{2,6}.0{8,10}]dodec-11-en-4- yl}-4-(trifluoromethyl)benzamide
| image = Tecovirimat.svg
| width = 200

| tradename =
| licence_EU =
| licence_US =
| pregnancy_US =
| legal_status = Prescription only (US)<ref>https://investor.siga.com/news-releases/news-release-details/us-food-and-drug-administration-approves-siga-technologies</ref>

| bioavailability =
| metabolism =
| excretion =

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID =
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = F925RR824R
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG =
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1242629
| synonyms = ST-246

| C=19 | H=15 | F=3 | N=2 | O=3
| molecular_weight = base: 376.3 g/mol
| smiles = FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)C2C(C3C=CC2C2CC32)C1=O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H15F3N2O3/c20-19(21,22)9-3-1-8(2-4-9)16(25)23-24-17(26)14-10-5-6-11(13-7-12(10)13)15(14)18(24)27/h1-6,10-15H,7H2,(H,23,25)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = CSKDFZIMJXRJGH-UHFFFAOYSA-N
}}

'''Tecovirimat''' ('''ST-246''' or '''Tpoxx''')<ref name="nyt-2018-07">{{cite web |last1=McNeil Jr. |first1=Donald G. |title=Drug to Treat Smallpox Approved by F.D.A., a Move Against Bioterrorism |url=https://www.nytimes.com/2018/07/13/health/smallpox-drug-fda-bioterrorism.html |website=The New York Times |publisher=The New York Times |accessdate=16 July 2018}}</ref> is an [[Antiviral drug|antiviral]] with activity against [[orthopoxviruses]] (such as [[smallpox]]) which is currently undergoing clinical trials. Originally researched by the [[National Institute of Allergy and Infectious Diseases]], the drug was previously owned by [[Viropharma]] and discovered in collaboration with scientists at [[USAMRIID]]. It is currently owned and manufactured by [[Siga Technologies]], a pharmaceutical company in the [[biodefense]] arena that won a government contract to develop the drug.

The drug works by blocking cellular transmission of the virus, thus preventing the disease. Tecovirimat has been effective in laboratory testing; it has been shown to protect animals from [[monkeypox]] and [[rabbitpox]] and causes no serious side effects in humans.<ref name="nyt-2018-07" /> However, tecovirimat has never been used to treat a human with smallpox due to the disease's successful eradication.

Two million doses of tecovirimat are stockpiled in the US [[Strategic National Stockpile]] as a defense against a smallpox outbreak.<ref>{{cite journal | doi = 10.1371/journal.ppat.1004108| pmid = 24789223| title = Are We There Yet? The Smallpox Research Agenda Using Variola Virus| journal = PLoS Pathogens| volume = 10| issue = 5| pages = e1004108| year = 2014| last1 = Damon| first1 = Inger K.| last2 = Damaso| first2 = Clarissa R.| last3 = McFadden| first3 = Grant| pmc=4006926}}</ref><ref>https://www.sciencenews.org/article/first-smallpox-treatment-one-step-closer-fda-approval</ref>

==Clinical study==
The results of clinical trials involving tecovirimat supports its use against smallpox and other related orthopoxviruses. It has shown potential for a variety of uses including [[prophylaxis]], as a post-exposure therapeutic, as a therapeutic and an adjunct to vaccination.<ref>[http://www.siga.com/index.php?ID=9 Siga Technologies]</ref>

Tecovirimat can be taken orally and has recently been granted permission to conduct Phase II trials by the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA). In phase I trials tecovirimat was generally well tolerated with no serious adverse events.<ref>{{cite journal | pmc = 2346641| year = 2008| author1 = Jordan| first1 = R| title = Single-Dose Safety and Pharmacokinetics of ST-246, a Novel Orthopoxvirus Egress Inhibitor| journal = Antimicrobial Agents and Chemotherapy| volume = 52| issue = 5| pages = 1721–1727| last2 = Tien| first2 = D| last3 = Bolken| first3 = T. C.| last4 = Jones| first4 = K. F.| last5 = Tyavanagimatt| first5 = S. R.| last6 = Strasser| first6 = J| last7 = Frimm| first7 = A| last8 = Corrado| first8 = M. L.| last9 = Strome| first9 = P. G.| last10 = Hruby| first10 = D. E.| doi = 10.1128/AAC.01303-07| pmid = 18316519}}</ref> Due to its importance for biodefense, the FDA has designated tecovirimat for 'fast-track' status, creating a path for expedited FDA review and eventual regulatory approval. On July 13, 2018, FDA announced approval of Tecovirimat.<ref>[https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm613496.htm U.S. Food and Drug Administration]</ref>

==Operating mechanism==
Tecovirimat inhibits the function of a major [[Viral envelope|envelope protein]] required for the production of extracellar virus. Thus the virus is prevented from leaving an infected cell and the spread of the virus within the body is prevented.<ref>{{cite journal | pmc = 1235851| year = 2005| author1 = Yang| first1 = G| title = An Orally Bioavailable Antipoxvirus Compound (ST-246) Inhibits Extracellular Virus Formation and Protects Mice from Lethal Orthopoxvirus Challenge| journal = Journal of Virology| volume = 79| issue = 20| pages = 13139–13149| last2 = Pevear| first2 = D. C.| last3 = Davies| first3 = M. H.| last4 = Collett| first4 = M. S.| last5 = Bailey| first5 = T| last6 = Rippen| first6 = S| last7 = Barone| first7 = L| last8 = Burns| first8 = C| last9 = Rhodes| first9 = G| last10 = Tohan| first10 = S| last11 = Huggins| first11 = J. W.| last12 = Baker| first12 = R. O.| last13 = Buller| first13 = R. L.| last14 = Touchette| first14 = E| last15 = Waller| first15 = K| last16 = Schriewer| first16 = J| last17 = Neyts| first17 = J| last18 = Declercq| first18 = E| last19 = Jones| first19 = K| last20 = Hruby| first20 = D| last21 = Jordan| first21 = R| doi = 10.1128/JVI.79.20.13139-13149.2005| pmid = 16189015}}</ref>

==References==
<references/>

[[Category:Antivirals]]
[[Category:Poxviruses]]
[[Category:Imides]]
[[Category:Hydrazides]]
[[Category:Experimental drugs]]
[[Category:Trifluoromethyl compounds]]
[[Category:Benzamides]]
[[Category:Nitrogen heterocycles]]
[[Category:Cyclopropanes]]

Tecovirimat

2018-07-16T02:44:59Z

DividedFrame: /* top */ Removed outdated information (FDA approval)

{{Drugbox
| verifiedrevid =
| IUPAC_name = ''N''-<nowiki/>{3,5-Dioxo-4- azatetracyclo[5.3.2.0{2,6}.0{8,10}]dodec-11-en-4- yl}-4-(trifluoromethyl)benzamide
| image = Tecovirimat.svg
| width = 200

| tradename =
| licence_EU =
| licence_US =
| pregnancy_US =
| legal_status = Prescription only (US)<ref>https://investor.siga.com/news-releases/news-release-details/us-food-and-drug-administration-approves-siga-technologies</ref>

| bioavailability =
| metabolism =
| excretion =

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID =
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = F925RR824R
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG =
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1242629
| synonyms = ST-246

| C=19 | H=15 | F=3 | N=2 | O=3
| molecular_weight = base: 376.3 g/mol
| smiles = FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)C2C(C3C=CC2C2CC32)C1=O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H15F3N2O3/c20-19(21,22)9-3-1-8(2-4-9)16(25)23-24-17(26)14-10-5-6-11(13-7-12(10)13)15(14)18(24)27/h1-6,10-15H,7H2,(H,23,25)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = CSKDFZIMJXRJGH-UHFFFAOYSA-N
}}

'''Tecovirimat''' ('''ST-246''') is an [[Antiviral drug|antiviral]] with activity against [[orthopoxviruses]] such as [[smallpox]] and is currently undergoing clinical trials. It was previously owned by [[Viropharma]] and discovered in collaboration with scientists at [[USAMRIID]]. It is currently owned and manufactured by [[Siga Technologies]], a drug development company in the [[biodefense]] arena. It works by blocking cellular transmission of the virus, thus preventing the disease. Tecovirimat has been effective in laboratory testing, with no serious side effects reported to date. Two million doses of tecovirimat are stockpiled in the US [[Strategic National Stockpile]] as a defense against a smallpox outbreak.<ref>{{cite journal | doi = 10.1371/journal.ppat.1004108| pmid = 24789223| title = Are We There Yet? The Smallpox Research Agenda Using Variola Virus| journal = PLoS Pathogens| volume = 10| issue = 5| pages = e1004108| year = 2014| last1 = Damon| first1 = Inger K.| last2 = Damaso| first2 = Clarissa R.| last3 = McFadden| first3 = Grant| pmc=4006926}}</ref><ref>https://www.sciencenews.org/article/first-smallpox-treatment-one-step-closer-fda-approval</ref>

==Clinical study==
The results of clinical trials involving tecovirimat supports its use against smallpox and other related orthopoxviruses. It has shown potential for a variety of uses including [[prophylaxis]], as a post-exposure therapeutic, as a therapeutic and an adjunct to vaccination.<ref>[http://www.siga.com/index.php?ID=9 Siga Technologies]</ref>

Tecovirimat can be taken orally and has recently been granted permission to conduct Phase II trials by the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA). In phase I trials tecovirimat was generally well tolerated with no serious adverse events.<ref>{{cite journal | pmc = 2346641| year = 2008| author1 = Jordan| first1 = R| title = Single-Dose Safety and Pharmacokinetics of ST-246, a Novel Orthopoxvirus Egress Inhibitor| journal = Antimicrobial Agents and Chemotherapy| volume = 52| issue = 5| pages = 1721–1727| last2 = Tien| first2 = D| last3 = Bolken| first3 = T. C.| last4 = Jones| first4 = K. F.| last5 = Tyavanagimatt| first5 = S. R.| last6 = Strasser| first6 = J| last7 = Frimm| first7 = A| last8 = Corrado| first8 = M. L.| last9 = Strome| first9 = P. G.| last10 = Hruby| first10 = D. E.| doi = 10.1128/AAC.01303-07| pmid = 18316519}}</ref> Due to its importance for biodefense, the FDA has designated tecovirimat for 'fast-track' status, creating a path for expedited FDA review and eventual regulatory approval. On July 13, 2018, FDA announced approval of Tecovirimat.<ref>[https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm613496.htm U.S. Food and Drug Administration]</ref>

==Operating mechanism==
Tecovirimat inhibits the function of a major [[Viral envelope|envelope protein]] required for the production of extracellar virus. Thus the virus is prevented from leaving an infected cell and the spread of the virus within the body is prevented.<ref>{{cite journal | pmc = 1235851| year = 2005| author1 = Yang| first1 = G| title = An Orally Bioavailable Antipoxvirus Compound (ST-246) Inhibits Extracellular Virus Formation and Protects Mice from Lethal Orthopoxvirus Challenge| journal = Journal of Virology| volume = 79| issue = 20| pages = 13139–13149| last2 = Pevear| first2 = D. C.| last3 = Davies| first3 = M. H.| last4 = Collett| first4 = M. S.| last5 = Bailey| first5 = T| last6 = Rippen| first6 = S| last7 = Barone| first7 = L| last8 = Burns| first8 = C| last9 = Rhodes| first9 = G| last10 = Tohan| first10 = S| last11 = Huggins| first11 = J. W.| last12 = Baker| first12 = R. O.| last13 = Buller| first13 = R. L.| last14 = Touchette| first14 = E| last15 = Waller| first15 = K| last16 = Schriewer| first16 = J| last17 = Neyts| first17 = J| last18 = Declercq| first18 = E| last19 = Jones| first19 = K| last20 = Hruby| first20 = D| last21 = Jordan| first21 = R| doi = 10.1128/JVI.79.20.13139-13149.2005| pmid = 16189015}}</ref>

==References==
<references/>

[[Category:Antivirals]]
[[Category:Poxviruses]]
[[Category:Imides]]
[[Category:Hydrazides]]
[[Category:Experimental drugs]]
[[Category:Trifluoromethyl compounds]]
[[Category:Benzamides]]
[[Category:Nitrogen heterocycles]]
[[Category:Cyclopropanes]]

Wikidata

2012-05-11T18:20:55Z

DividedFrame:

'''Wikidata''' is a proposed project to provide a collaboratively edited database to support [[Wikipedia]]. The project is being started by [[Wikimedia Deutschland]] and is intended to provide a common source of certain data types, for example, birth dates, a class of validated data, which can be used in all other articles on Wikipedia.<ref>{{cite news |title=Data Revolution for Wikipedia |url=http://www.marketwatch.com/story/data-revolution-for-wikipedia-2012-03-30 |work=[[MarketWatch]] |date=March 30, 2012 |accessdate=April 10, 2012}}</ref> It will be the first new project of the [[Wikimedia Foundation]] since 2006.<ref>{{cite news |title=The Wikipedia data revolution |first=Matthew |last=Roth |url=http://blog.wikimedia.org/2012/03/30/the-wikipedia-data-revolution/ |publisher=[[Wikimedia Foundation]] |date=March 30, 2012 |accessdate=April 10, 2012}}</ref>

The creation of the project was funded by donations from the [[Allen Institute for Artificial Intelligence]], the [[Gordon and Betty Moore Foundation]], and [[Google, Inc.]], totaling [[Euro|€]]1.3 million.<ref>{{cite news |title=Paul Allen Invests In A Massive Project To Make Wikipedia Better |first=Boonsri |last=Dickinson |url=http://articles.businessinsider.com/2012-03-30/tech/31259697_1_wikimedia-foundation-wikipedia-project |newspaper=[[Business Insider]] |date=March 30, 2012 |accessdate=April 10, 2012}}</ref><ref>{{cite news |title=Wikipedia’s Next Big Thing: Wikidata, A Machine-Readable, User-Editable Database Funded By Google, Paul Allen And Others |first=Sarah |last=Perez |url=http://techcrunch.com/2012/03/30/wikipedias-next-big-thing-wikidata-a-machine-readable-user-editable-database-funded-by-google-paul-allen-and-others/ |newspaper=[[TechCrunch]] |date=March 30, 2012 |accessdate=April 10, 2012}}</ref>

==References==
{{reflist}}

==External links==
* {{official|http://meta.wikimedia.org/wiki/Wikidata}}

{{Wikimedia Foundation}}

[[Category:Wikimedia projects]]
[[Category:2013 introductions]]
[[Category:Databases]]
{{internet-stub}}

[[fa:ویکی‌داده]]
[[fr:Wikidata]]